Inactive Instrument

Advaxis, Inc. Stock price OTC Bulletin Board

Equities

US0076241092

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD 0.00% Intraday chart for Advaxis, Inc.
Sales 2023 * - Sales 2024 * - Capitalization 29.84M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 0%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 59 18-04-22
Chief Tech/Sci/R&D Officer 63 18-04-22
- -
Members of the board TitleAgeSince
Chairman 64 13-07-15
Chief Executive Officer 57 04-10-31
Director/Board Member 79 23-01-18
More insiders
Ayala Pharmaceuticals, Inc., formerly Advaxis, Inc., is a clinical-stage oncology company. The Company is focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. It is also developing Lm-based antigen delivery products for patients suffering from more common cancers. The Company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors, including desmoid tumors, and ADXS-504, a Lm-based therapy for early-stage prostate cancer. It uses a combination of sequencing and its bioinformatics platform to help develop Notch-targeted therapies. It is evaluating AL102 in its Phase II/III RINGSIDE trial for the treatment of patients with progressing desmoid tumors. It is also evaluating AL101 in a Phase II trial for the treatment of patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
More about the company
  1. Stock
  2. Equities
  3. Stock Ayala Pharmaceuticals, Inc.
  4. Stock Advaxis, Inc. - OTC Bulletin Board